際華集團(601718.SH)擬向控股股東轉讓2家子公司100%股權和合計7.94億元債權
格隆匯12月6日丨際華集團(601718.SH)公佈,為貫徹公司聚焦主業、突出實業的戰略要求,進一步優化公司資產和業務結構、促進資源有效配置,有效解決與控股股東的潛在同業競爭,公司擬向控股股東新興際華轉讓公司所持有的天津華津製藥有限公司(以下簡稱“華津製藥”)100%股權、際華三五二三特種裝備有限公司(以下簡稱“3523公司”)100%股權,以及公司對華津製藥和3523公司的債權7.94億元。
其中華津製藥100%股權的轉讓價格為6.91億元,3523公司100%股權的轉讓價格為3234.12萬元,股權轉讓價格合計為7.23億元,新興際華以其持有的新興際華投資有限公司(簡稱“新興際華投資”)17.53%股權作為交易的支付對價。
經第三方審計機構出具的審計報告確定,公司對華津製藥和3523公司的債權合計金額為7.94億元(其中對華津製藥的債權為5億元,對3523公司的債權為2.94億元),本次交易中公司將對華津製藥和3523公司的債權7.94億元以現金方式轉讓給新興際華,轉讓價格為7.94億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.